Beta-blockers in the treatment of uncomplicated hypertension: the current state of the problem
https://doi.org/10.38109/2075-082X-2025-4-69-71
Abstract
The article is devoted to one of the most controversial issues in the treatment of uncomplicated arterial hypertension (AH) – the role of beta-blockers (BB). For a long time, BB were not recommended as a first-line drugs for uncomplicated AH management. The most important role BB have in case of treatment of the uncomplicated AH with an increased heart rate (HR > 80’). Despite the lack of strict evidence for the BB efficacy in patients with uncomplicated AH and an increased HR, experts are increasingly confident in the advisability of this drug class using. In this regard, the reporting on the latest domestic and foreign recommendations of the BB need to be used in various clinical situations, including uncomplicated AH and high HR, is a very important event. In fact, these recommendations return BB to the list of main classes of antihypertensive drugs in uncomplicated AH management.
It was also noted that preference should be given to selective BB to increase therapy safety and reduce the risk of adverse metabolic effects.
About the Author
D. V. Nebieridze
National Medical Research Center for Therapy and Preventive Medicine, 10 Petroverigsky Lane, building 3, Moscow 101000, Russian Federation
Russian Federation
Russian Federation
David V. Nebieridze, Dr. of Scien. (Med.), Professor, Head of the Department of Metabolic Disorders Prevention
10 Petroverigsky Lane, Building 3, Moscow 101000
References
1. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA) [published correction appears in J Hypertens. 2024 Jan 1;42(1):194. https://doi.org/10.1097/hjh.0000000000003621]. J Hypertens. 2023;41(12):1874-2071. https://doi.org/10.1097/HJH.0000000000003480
2. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.).] https://doi.org/10.15829/1560
3. Williams B., Poulter N.R., Brown M.J. et al. Guidelines for management of hy-pertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004 Mar;18(3):139-85. https://doi.org/10.1038/sj.jhh.1001683
4. Lindholm L.H., Carlberg B., Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet . 2005;366(9496):1545-53. https://doi.org/10.1016/s0140-6736(05)67573-3
5. Wikstrand J., Warnold I., Tuomilehto J. et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension . 1991 Apr;17(4):579-88. https://doi.org/10.1161/01.hyp.17.4.579
6. Messerli, Franz H, and Ehud Grossman. “beta-Blockers in hypertension: is carvedilol different?” Am J Cardiol. 2004 May 6;93(9A):7B-12B. https://doi.org/10.1016/j.amjcard.2004.01.020
7. Wojciechowski, David, and Vasilios Papademetriou. “Beta-blockers in the management of hypertension: focus on nebivolol.” Expert Rev Cardiovasc Ther. 2008 Apr;6(4):471-9. https://doi.org/10.1586/14779072.6.4.471
8. Lewis, R et al. “A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension.” British journal of clinical pharmacology vol. 26,1 (1988): 53-9. https://doi.org/10.1111/j.1365-2125.1988.tb03363.x
9. Cruickshank, J M. “Are we misunderstanding beta-blockers.” International journal of cardiology vol. 120,1 (2007):10-27. https://doi.org/10.1016/j.ijcard.2007.01.069
10. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462-1536. https://doi.org/10.1093/eurheartj/ehm236
11. Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31. https://doi.org/10.26442/2075082X.2019.1.190179]
12. Balanova YuA, Shalnova SA, Kutsenko VA, et al. Contribution of hypertension and other risk factors to survival and mortality in the Russian population. Cardiovascular Therapy and Prevention. 2021;20(5):3003. (In Russ.) https://doi.org/10.15829/1728-8800-2021-3003]
13. Palatini P. Role of Elevated Heart Rate in the Development of Cardiovascular Disease in Hypertension. Hypertension. 2011;58(5):745-750. https://doi.org/10.1161/HYPERTENSIONAHA.111.173104
14. Barbarash OL, Karpov YuA, Panov AV, et al. 2024 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2024;29(9):6110. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6110]
15. Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3415-3537. https://doi.org/10.1093/eurheartj/ehae177
16. Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6162]
17. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M,Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension. Eur Heart J. 2018;39 (33):3021–3104. https://doi.org/10.1093/eurheartj/ehy339
18. Konradi A.О., Karpov Yu.A., Shalnova S.A., Koziolova N.A., Matskeplishvili S.T., Nedogoda S.V., Gilyarevskiy S.R., Kashtalap V.V., Kisliak O.A., Zyryanov S.K., Zhirov I.V. Management of patients with arterial hypertension and heart rate over 80 bpm: resolution of the expert council. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2025;31(2):82-97. (In Russ.) EDN: YFWBPL. https://doi.org/10.18705/1607-419X-2025-2525]
Review
For citations:
Nebieridze D.V. Beta-blockers in the treatment of uncomplicated hypertension: the current state of the problem. Systemic Hypertension. 2025;22(4):69-71. (In Russ.) https://doi.org/10.38109/2075-082X-2025-4-69-71
Views:
414
JATS XML
Email this article 